UTILITY PATENT APPLICATION TRANSMITTAL

	Pater	nt an	emark C	Office: U.S. DEPARTMENT OF COMMERC
Attorney Doc	cket No.	PC9	985A	
First Named Inventor or Application			Identifier	. YOSHINOBU HASHIZUME
Title Aryl or heteroary			fused im	idazole compounds as anti- ic agents.
inflammatory and			EL446402	2562US

		I KAN2MII I	. ,	1	inflam	matory a	nu ana	igesic agents.			
' h			Express Mail	Express Mail Label No.		EL4	EL446402562US				
(Only for new nonprovisional applications under 37C.F.R. §1.53(b))						Commissioner for Patents				2 =	
						DDRESS T	J.	Rox Patent Appli	cation	る一重	
		APPLICATION	LELEMENTS	ntoats	A	JUNE33 I	J. 	Washington, DC	20231	23	
See MPEP chapter 600 concerning utility patent application contents.					Microf	obo Com	nputer Program (A	ppendix)	"三 重		
	\overline{N} .	- Tmittal Form	n (e.g., PTO/SB/17) plicate for fee processing)		6. L	ucleotide a	nd/or Am	nino Acid Sequenc		9/6/	
2.	∇	Specification	[Total Pages	367	i. (i	f applicable	, all nece	essary)		011	
	(t	oreferred arrangements - Descriptive title of	nt set lortil below)			a. 🔼	Comp	uter Readable Cop	У	1	
		- Descriptive title of	to Related Application	ons			Paper	Copy (identical to	computer copy	<i>'</i>)	
		Statement Regard	ding Fed sponsored F	R&D	b. Paper Copy (identical to compare) C. Statement verifying identity of above copies						
		- Reference in Mici	rofiche Appendix		c. Statement verifying identity of above ACCOMPANYING APPLICATION PARTS						
		- Background of th									
		 Brief Summary of Brief Description Detailed Description Claim(s) 	f the Invention of the Drawings (if fil tion	ed)	8. 9.	37 C. (whe	F.R. §3.73 n there i	Papers (cover shee B(b) Statement s an assignee)	Power	s)) of Attorney	
		- Abstract of the D	oisclosure		10.	Engl	ish Trans	slation Document (_	
3	. [-]	Drawing(e) (3511.5	C. 11.3)[Total sheets		11.	Info	mation [ement (II	Disclosure DS)/PTO-1449	Copies Citation		
4		Oath or Declaration			12.			Amendment			
	. (2)	•	cuted (original or cop	y)	13.	13. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
1					1			Statem	ent filed in price	r application,	
§1.63(d)) §1.63(d)) Status still proper and desired (proper status still proper and desired)							desired				
		_	[Note Box 5 pero	wj	1			ppy of Priority Docu	ument(s)		
1		i	DELETION OF INVE	NTOR(S)	15.	(if	foreian p	riority is claimed)			
1		Signed st	atement attached del	eung application,	1	V					
1		inventor(s	F.R. §§1.63(d)(2) and	d 1.33(b).	1						
1			Poference (useable if I	Box 4b is checke	a) 16.	Ot	her:	Priority Claim		- 11 0 100	
5	The	entire disclosure of t y of the oath or decla	the prior application, in the prior application is supplied und	der Box 4b, is accompanying	1			60/241,825	filed l	.0/19/00	
1	app	lication and is hereby	y incorporated by refe	rence therein.	L		====	ORDER TO BE ENTIT	ED TO PAY SMAL	L ENTITY	
					FEE	S, A SMALL E	PRIOR A	PPLICATION IS RELIED	UPON (37 C.F.R.	§ 1.28).	
1			PLICATION, check ap	propriate box ar	nd supply	the requisite	informatio	n below and in a prel	iminary amendm	ent:	
	17. lf			Cartinu	ation-in-r	art (CIP)	a	f prior application	No:/		
1	Ĺ	Continuation	Divisional		311011-111-			Group/Art U			
ł	F	Prior application infor			ECDO	NDENCE A	NDDRE	SS			
Ī			18	Customer No. or				abla	ondence address	below	
t	Cu	ustomer Number or Bar	(Insert C	customer No. or				or Correspo	muence audress		
ł	Name	Paul H. Ginsb									
Ī	Addres	ss Pfizer Inc									
Address 235 East 42nd Street, 20th Floor		64-4-		New York		Zip Code	10017-5755				
	City	New York		State				Fax	(212)573-19	939 T	
Country		ry United States	Of America ELSA DJUARDI	Telephone	P	Registration No. (Atte		orney/Agent)	45,963		
1		NAME (Print/type)									

PTO/SB/17(2/98)
Approved for use through 09/30/2000.
OMB 0651-0032 Palest and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	S.m. satt				plete if Known			
	Application Number				nassigned			
FEE TRANSMITTAL	Filing Date				oncurrent herewith			
Patent fees are subject to annual revision on October 1.	First Named Inventor				OSHINOBU HASHIZUME			
These are the fees effective October 1, 2001.	Examiner	Name			Unassigne			
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.	- (A ed	Lloit			Unassigned			
See 37 C.F.R. §§ 1.27 and 1.28.	Group/Art Attorney I		No		PC9985A			
Total Amount of Payment (\$)740.00	Allonley	DOCKE	10.	FF CAL	CULATION (continued)			
METHOD OF PAYMENT (check one)	3. ADDITIO	NAL FE			,			
1. The commissioner is hereby authorized to charge	Large En		Small En	tity				
indicated fees and credit any over payments to:		Fee	Fee Code	Fee (\$)	Fee Description Fee Paid			
Account Number 16-1445	105	130	205	65	Surcharge – late fee or oath			
Deposit Account Pfizer Inc Name	103	100						
	127	50	227	25	Surcharge-late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing 37 C.F.R. § 1.18 at the Mailing	139	130	139	130	Non-English specification			
37 C.F.R. §§ 1.16 and 1.17. of the Notice of Allowance.	147	2,520	147	2,520	For filing a request for reexamination			
	112	920*	112	920*	Requesting publication of SIR prior to			
2. Payment Enclosed: Check Money Order Other	113	1,840*	113	1,840*	Examiner action Requesting publication of SIR after Examiner action			
Check Money order	115	110	215	55	Extension for reply within first month			
FEE CALCULATION 1 BASIC FILING FEE	116	400	216	200	Extension for reply within second month			
The state of the s	117	920	217	460	Extension for reply within third month			
Large Entity Small Entity Large Entity Small Entity Fee Fee Fee Fee Fee Description Fee Paid	118	1,440	218	720	Extension for reply within fourth month			
Code (\$) Code (\$)	128	1,960	228	980	Extension for reply within fifth month			
740 201 370 Guilly lilling lec	119	320	219	160	Notice of Appeal Filing a brief in support of an appeal			
107 510 207 255 Plant filing fee	120	320 280	220 221	160 140	Request for oral hearing			
1408 740 208 370 Reissue filing fee	121 138	1,510		1,510	Petition to institute a public use			
160 214 80 Provisional filing fee 740.00	140	110	240	55	proceeding Petition to revive - unavoidable			
SUBTOTAL (1) (3)	141	1,280	241	640	Petition to revive - unintentional			
ZEXTRA CLAIM FEES Extra Fee from Fee Paid	142	1,280		640	Utility issue fee (or reissue)			
Claims below Feb and Total Claims Total Cla	0 143	460	243	230				
Independent - 3**= X = =	144	620	244	310				
Claims =	122	130		130				
** or number previously paid, if greater; For Reissues, see below	123	50	123	50	applications			
Fee Fee Fee Fee Description	126	180		180	Statement Recording each patent assignment per			
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581	40	581	40	property (times number of properties)			
102 84 42 Independent claims in excess of 3	146	740	246	370	(37 CFR 1.129(a))			
202 104 280 204 140 Multiple dependent claim, if not paid	149	740		370				
109 84 209 42 **Reissue independent claims over original patent	ł	Fee (spe						
110 18 210 9 **Reissue claims in excess of 20 and over original patent		Other Fee (specify) *Reduced by Basic Filing Fee Page 19 Page			id SUBTOTAL (3) (\$)			
SUBTOTAL (2) (\$)	*Redu	icea by E	asic Fliing	, 1 ee Fa	Complete (if Applicable)			
SUBMITTED BY					Reg. Number 45,963			
Type or Printed Name ELSA DJUARDI	Date				Deposit Account			
Signature Gladim		5101			User ID			





PATENT	APPLICATION	SERIAL	NO.	 	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

10/18/2001 MMEKONEN 00000081 161445 09977621

01 FC:101 02 FC:102 740.00 CH 84.00 CH

Adjustment date: 01/17/2002 CVORACHA
10/18/2001 NMEKONEN 00000081 161445 09977621
02 FC:102 84.00 CR